Metraipolis › archive › dc_97ef80b04c4e

Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency — Europe PMC PMID:40903342

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40903342
DOI
10.1016/j.neurot.2025.e00727
License (as archived)
solo-consultazione
Archived
2026-11-10T04:42:44.468Z
SHA-256 of the archived text
2cc5f8501ee0d80c00575a7b4d9b632a81402d5dbcbd18210a5803b0b468a3a8
Stable URL of this page
https://metraipolis.com/documento/dc_97ef80b04c4e

How to cite

Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency — Europe PMC PMID:40903342 — Europe PMC (en), https://europepmc.org/article/MED/40903342 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97ef80b04c4e (Metraipolis archive dc_97ef80b04c4e, sha256 2cc5f8501ee0d80c00575a7b4d9b632a81402d5dbcbd18210a5803b0b468a3a8)
BibTeX
@misc{dc97ef80b04c4e,
  title = {Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency — Europe PMC PMID:40903342},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40903342},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97ef80b04c4e; sha256 2cc5f8501ee0d80c00575a7b4d9b632a81402d5dbcbd18210a5803b0b468a3a8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40903342. Agents can read the archived copy with the MCP tool read_document.